Technical Analysis for EXEL - Exelixis, Inc.

Grade Last Price % Change Price Change
grade D 16.51 -0.90% -0.15
EXEL closed down 0.9 percent on Friday, November 15, 2019, on 81 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical EXEL trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.90%
20 DMA Support Bullish -0.90%
New Uptrend Bullish -0.90%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.86%
Crossed Above 20 DMA Bullish 0.86%
MACD Bullish Signal Line Cross Bullish 0.86%
1,2,3 Retracement Bearish Bearish Swing Setup 7.63%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 7.63%

Older signals for EXEL ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer in the United States. It focuses on developing and commercializing COMETRIQ (cabozantinib), an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive, metastatic medullary thyroid cancer. COMETRIQ is also involved in various other cancer indications, including two ongoing Phase III pivotal trials in metastatic castration-resistant prostate cancer; and two additional Phase III pivotal trials in metastatic hepatocellular cancer and metastatic renal cell cancer. In addition, the company has a portfolio of other novel compounds that address serious unmet medical needs. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company, Sanofi, Genentech, Inc., GlaxoSmithKline, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Chemistry Biotechnology Cancer Treatment Of Cancer Cyclopropanes Sanofi Tyrosine Kinase Inhibitors Protein Kinase Inhibitor Genentech Small Molecule Therapies Metastatic Castration Resistant Prostate Cancer
Is EXEL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 25.31
52 Week Low 15.02
Average Volume 2,661,744
200-Day Moving Average 20.3501
50-Day Moving Average 17.3318
20-Day Moving Average 16.2973
10-Day Moving Average 15.823
Average True Range 0.6493
ADX 24.95
+DI 21.9976
-DI 20.2086
Chandelier Exit (Long, 3 ATRs ) 15.5321
Chandelier Exit (Short, 3 ATRs ) 16.9679
Upper Bollinger Band 17.6944
Lower Bollinger Band 14.9002
Percent B (%b) 0.58
BandWidth 17.145171
MACD Line -0.3492
MACD Signal Line -0.4854
MACD Histogram 0.1362
Fundamentals Value
Market Cap 4.85 Billion
Num Shares 294 Million
EPS 0.20
Price-to-Earnings (P/E) Ratio 82.55
Price-to-Sales 23.83
Price-to-Book 51.23
PEG Ratio 2.01
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.17
Resistance 3 (R3) 17.19 17.00 17.06
Resistance 2 (R2) 17.00 16.83 16.99 17.02
Resistance 1 (R1) 16.75 16.72 16.66 16.73 16.99
Pivot Point 16.56 16.56 16.51 16.55 16.56
Support 1 (S1) 16.31 16.39 16.22 16.29 16.03
Support 2 (S2) 16.12 16.28 16.11 16.00
Support 3 (S3) 15.87 16.12 15.96
Support 4 (S4) 15.85